CD34+ Megakaryoblastic Leukaemic Cells Are CD38−, but CD61+ and Glycophorin A+: Improved Criteria for Diagnosis of AML-M7?

Leukemia - United Kingdom
doi 10.1038/sj.leu.2400648
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

A Case of Acute Megakaryoblastic Leukaemia (FAB M7), a Rare Type of Acute Myeloid Leukemia (AML), in a Teenager

Malawi Medical Journal
Medicine
2018English

Double Lineage Switch From Acute Megakaryoblastic Leukemia (AML-M7) to Acute Lymphoblastic Leukemia (ALL) and Back Again: A Case Report

Journal of Blood Disorders & Transfusion
2014English

Wnt1 Accelerates anEx VivoExpansion of Human Cord Blood CD34+CD38−Cells

Stem Cells International
Cell BiologyMolecular Biology
2013English

Leukaemic Blast Cannibalism in Acute Megakaryoblastic Leukaemia With Myeloid Sarcoma

British Journal of Haematology
Hematology
2016English

Delta-1 Enhances Marrow and Thymus Repopulating Ability of Human CD34+CD38– Cord Blood Cells

Journal of Clinical Investigation
Medicine
2002English

Stable Transduction of Quiescent CD34+CD38- Human Hematopoietic Cells by HIV-1-based Lentiviral Vectors

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1999English

Skeletal Muscle–Derived CD34+/45-and CD34-/45-Stem Cells Are Situated Hierarchically Upstream of Pax7+Cells

Stem Cells and Development
Developmental BiologyHematologyCell Biology
2008English

Presence of CD34+CD38−CD58− Leukemia-Propagating Cells at Diagnosis Identifies Patients at High Risk of Relapse With Ph Chromosome-Positive ALL After Allo-Hematopoietic SCT

Bone Marrow Transplantation
TransplantationHematology
2014English

In Vitro Transformation of Primary Human CD34+ Cells by AML Fusion Oncogenes: Early Gene Expression Profiling Reveals Possible Drug Target in AML

PLoS ONE
Multidisciplinary
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy